- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about UK:AZN
Recent news which mentions UK:AZN
Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk’s Ozempic
December 04, 2023
From MarketWatch
AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines
November 09, 2023
Tickers
AZN
From MarketWatch
Here’s what Ozempic, ASML and India’s fintech industry all have in common — and how one ETF takes advantage of all three
October 17, 2023
From MarketWatch
Startup Cerebras stands out in the high-risk AI chip arena: ‘No one has built a chip this big’
October 11, 2023
From MarketWatch
This fund shows that industry expertise can help you make a lot of money in the stock market
October 02, 2023
From MarketWatch
JPMorgan says there may be many oil crises this decade as it lifts rating on energy stocks
September 22, 2023
From MarketWatch
As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
July 21, 2023
From MarketWatch
Tickers
AZN
From MarketWatch
AstraZeneca to decarbonize U.S. footprint by turning cow manure into renewable natural gas
June 13, 2023
From MarketWatch
Tickers
AZN
From MarketWatch
From MarketWatch
AstraZeneca says cancer drug Enhertu showed positive results
March 06, 2023
Tickers
AZN
From MarketWatch
FTSE 100 hits fresh record above 8,000 on weak pound and renewed demand for energy stocks
February 16, 2023
From MarketWatch
Tickers
AZN
From MarketWatch
AstraZeneca says Forxiga approved in EU for heart failure
February 07, 2023
Tickers
AZN
From MarketWatch
Drug companies plan to raise prices on vital medicines to fund R&D, but they already spend more on shareholder returns
January 13, 2023
From MarketWatch
Will 2023 be the year that pharma M&A makes a comeback?
January 12, 2023
From MarketWatch
From MarketWatch
Powell won’t stop rate hikes until he ‘terrifies’ the wealthiest of investors, says this CIO
January 09, 2023
From MarketWatch
AstraZeneca will buy U.S.-based CinCor for cardiorenal asset
January 09, 2023
From MarketWatch
AstraZeneca’s Forxiga gets EU approval recommendation for symptomatic chronic heart failure
December 19, 2022
Tickers
AZN
From MarketWatch
AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU
December 19, 2022
Tickers
AZN
From MarketWatch
Netflix, Workday, Costco, Caterpillar and more: These stocks are Cowen’s favorites for 2023
December 10, 2022
From MarketWatch
AstraZeneca lifts guidance after forecast-beating profit and sales
November 10, 2022
Tickers
AZN
From MarketWatch
From MarketWatch
AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints
October 26, 2022
Tickers
AZN
From MarketWatch
From MarketWatch
Europe may give COVID vaccines full marketing authorization to avoid annual review, and WHO backs Gilead’s Veklury for severe disease
September 16, 2022
From MarketWatch
AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say
September 14, 2022
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.